ROCKET PHARMACEUTICALS, INC. short interest in 2026
In 2026, ROCKET PHARMACEUTICALS, INC.'s disclosed short interest ran from 12.37% of shares outstanding on 15 Jan 2026 to 13.53% on 15 Sep 2026, a change of +1.16 percentage points. The year's high was 20.56% on 29 May 2026 and its low 12.37% on 15 Jan 2026, averaging 15.62% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.90 days on 31 Jul 2026. Full history: ROCKET PHARMACEUTICALS, INC..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 12.37% (15 Jan 2026)
- End of year
- 13.53% (15 Sep 2026)
- Change
- +1.16 pp
- High
- 20.56% (29 May 2026)
- Low
- 12.37% (15 Jan 2026)
- Average
- 15.62%
- Highest days to cover
- 11.90 (31 Jul 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 12.37% | 5.96 | |
| 30 Jan 2026 | 12.86% | 6.20 | |
| 13 Feb 2026 | 13.36% | 7.93 | |
| 27 Feb 2026 | 12.92% | 4.99 | 10-K filed, results (8-K) |
| 13 Mar 2026 | 13.58% | 4.31 | |
| 31 Mar 2026 | 17.17% | 2.89 | |
| 15 Apr 2026 | 17.63% | 7.32 | |
| 30 Apr 2026 | 19.91% | 10.69 | |
| 15 May 2026 | 19.19% | 10.09 | 10-Q filed, results (8-K) |
| 29 May 2026 | 20.56% | 9.52 | |
| 15 Jun 2026 | 20.06% | 8.35 | |
| 30 Jun 2026 | 16.63% | 4.98 | |
| 15 Jul 2026 | 15.18% | 6.80 | |
| 31 Jul 2026 | 14.12% | 11.90 | |
| 14 Aug 2026 | 13.11% | 8.56 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 13.40% | 9.79 | |
| 15 Sep 2026 | 13.53% | 11.10 |
See also: ROCKET PHARMACEUTICALS, INC.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.